Valuation : Protagonist Therapeutics, Inc.

Market Cap 9.43B 8.11B 7.63B 6.97B 13.05B 890B 13.08B 90.21B 35.01B 457B 35.41B 34.64B 1,472B P/E 2026 *
31.3x
P/E 2027 * -307x
Enterprise Value 8.89B 7.65B 7.2B 6.58B 12.3B 839B 12.33B 85.06B 33.01B 431B 33.39B 32.66B 1,388B EV / Sales 2026 *
16.4x
EV / Sales 2027 * 43.8x
Free-Float
97.68%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Protagonist Therapeutics, Inc.

1 day-2.07%
1 week+0.96%
Current month-1.37%
1 month+6.12%
3 months+49.64%
6 months+59.41%
Current year+66.84%
1 week 141.95
Extreme 141.9479
150.34
1 month 141.95
Extreme 141.9479
160.81
Current year 77
Extreme 77
160.81
1 year 54.5
Extreme 54.5
160.81
3 years 13.72
Extreme 13.72
160.81
5 years 6.91
Extreme 6.91
160.81
10 years 4.47
Extreme 4.47
160.81
Manager TitleAgeSince
Chief Executive Officer 69 30/11/2008
Director of Finance/CFO 52 17/04/2022
Chief Tech/Sci/R&D Officer - 31/03/2026
Director TitleAgeSince
Director/Board Member 69 30/11/2008
Chairman 71 18/03/2014
Director/Board Member 69 30/06/2016
Date Insider Type Main position Quantity % Market Cap. Importance
11/08/26 Exercice

Chief Executive Officer

102,717 0.1597%
10/06/26 Exercice

Director

27,000 0.0420%
29/05/26 Exercice

Director

27,000 0.0420%
Change 5-day change 1-year change 3-year change Capi.($)
-2.07%+0.96%+140.74%+644.61% 9.43B
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -1.03%+0.58%+81.46%+169.08% 28.44B
Weighted average by Cap. -1.07%+0.14%+91.23%+146.20%

Financials

2026 *2027 *
Net sales 542M 467M 439M 401M 750M 51.2B 752M 5.19B 2.01B 26.27B 2.04B 1.99B 84.63B 203M 175M 165M 150M 281M 19.21B 282M 1.95B 755M 9.85B 764M 747M 31.74B
Net income 324M 279M 262M 239M 448M 30.57B 449M 3.1B 1.2B 15.68B 1.22B 1.19B 50.53B -32.12M -27.64M -26.01M -23.76M -44.44M -3.03B -44.56M -307M -119M -1.56B -121M -118M -5.01B
Net Debt -538M -463M -436M -398M -745M -50.82B -747M -5.15B -2B -26.07B -2.02B -1.98B -84B -511M -440M -414M -378M -707M -48.25B -709M -4.89B -1.9B -24.76B -1.92B -1.88B -79.76B
Logo Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).
Employees
141
Date Price Change Volume
04/09/26 US$145.72 -2.07% 501,305
03/09/26 US$148.80 +1.86% 354,191
02/09/26 US$146.08 -0.28% 561,612
01/09/26 US$146.49 -0.85% 534,144
31/08/26 US$147.75 +2.37% 567,395
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
145.72USD
Average target price
174.69USD
Spread / Average Target
+19.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTGX Stock